Expert Review of Vaccines

Adjuvants: progress, regress and pandemic preparedness
pp. 651-652(2)
Authors: Glenn, Gregory M; O'Hagan, Derek T

New smallpox vaccine approved by US FDA
pp. 653-655(3)

Phase I/II study launched for adjuvant patches
pp. 657-657(1)

MF59™-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations
pp. 659-665(7)
Authors: Puig Barberà, Joan; González Vidal, David

B cells as a cellular adjuvant: induction or control of T-cell immunity - or both?
pp. 667-671(5)
Author: von Bergwelt-Baildon, Michael

The science of adjuvants
pp. 673-684(12)
Authors: Kwissa, Marcin; Pai Kasturi, Sudhir; Pulendran, Bali

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation
pp. 685-698(14)
Authors: Hem, Stanley L; HogenEsch, Harm

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
pp. 699-710(12)
Author: O'Hagan, Derek T

Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations
pp. 711-721(11)
Authors: Moser, Christian; Amacker, Mario; Kammer, Andreas R; Rasi, Silvia; Westerfeld, Nicole; Zurbriggen, Rinaldo

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
pp. 723-739(17)
Authors: Garçon, Nathalie; Chomez, Patrick; Van Mechelen, Marcelle

IC31^® and IC30, novel types of vaccine adjuvant based on peptide delivery systems
pp. 741-746(6)
Authors: Lingnau, Karen; Riedl, Karin; von Gabain, Alexander

Immunostimulatory DNA as a vaccine adjuvant
pp. 747-759(13)
Authors: Higgins, Debbie; Marshall, Jason D; Traquina, Paula; Van Nest, Gary; Livingston, Brian D

ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines
pp. 761-772(12)
Authors: Drane, Debbie; Gittleson, Charmaine; Boyle, Jeff; Maraskovsky, Eugene

E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant
pp. 773-784(12)
Authors: Ishizaka, Sally T; Hawkins, Lynn D

Cationic liposomes as vaccine adjuvants
pp. 785-796(12)
Authors: Christensen, Dennis; Korsholm, Karen S; Rosenkrands, Ida; Lindenstrøm, Thomas; Andersen, Peter; Agger, Else Marie

Nanoparticles and microparticles as vaccine-delivery systems
pp. 797-808(12)
Authors: Singh, Manmohan; Chakrapani, Aravind; O'Hagan, Derek

Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch
pp. 809-819(11)
Authors: Glenn, Gregory M; Flyer, David C; Ellingsworth, Larry R; Frech, Sarah A; Frerichs, David M; Seid, Robert C; Yu, Jianmei

Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by Type I and Type II heat-labile enterotoxins
pp. 821-834(14)
Author: Connell, Terry D

Resiquimod and other immune response modifiers as vaccine adjuvants
pp. 835-847(13)
Authors: Tomai, Mark A; Miller, Richard L; Lipson, Kenneth E; Kieper, William C; Zarraga, Isidro E; Vasilakos, John P

New adjuvants: EU regulatory developments
pp. 849-861(13)
Authors: Sesardic, Dorothea; Rijpkema, Sjoerd; Patel, Brijesh Prakash

Neurological adverse events of immunization: experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine
pp. 863-869(7)
Authors: Nøkleby, Hanne